The call highlighted significant clinical progress, strategic partnerships, and operational efficiency, with substantial advancements in solid tumor and ARDS treatments. Although there was a delay in government funding, the overall sentiment remains positive due to the strong performance and strategic advancements.

Company Guidance -

Q2 2025

During the first quarter of 2025, MiNK Therapeutics reported significant progress in several key areas, focusing primarily on their scalable iNKT cell therapies for solid tumors and immune-related diseases. The company achieved a 47% year-on-year reduction in operating cash burn, maintaining financial efficiency to support core program investments. In their clinical trials, MiNK made strides with their second-line gastric cancer program and continued development in ARDS and GvHD. Their strategic initiatives included advancing confidential proposals that could enhance their operational runway and accelerate impact. These proposals focus on oncology, immunology, and their next-generation pipeline, aiming to leverage distinct partner capabilities to foster growth. MiNK highlighted compelling clinical data, including a complete response in a metastatic testicular cancer patient and promising survival rates in ARDS cases. Financially, the company ended the quarter with $3.2 million in cash, reducing the net loss to $2.8 million, or $0.70 per share, compared to $3.8 million, or $1.10 per share, in the previous year.

Clinical Progress in Solid Tumors

Presented new data in solid tumors, specifically in second-line gastric cancer, showing immune activation and very early clinical activity in patients refractory to checkpoint modulating antibodies.

Capital Efficiency

Continued reduction in operating cash burn by about 47% year-on-year, preserving the ability to invest in core programs.

Strategic Partnerships

Advancing three distinct proposals aligned with key therapeutic areas in oncology, cancer, and immunology, which could extend runway and accelerate impact.

Testicular Cancer Complete Response

Reported a complete response in a patient with metastatic testicular cancer treated with agenT-797, achieving durable remission without lymphodepletion or HLA matching.

Advancements in ARDS Treatment

Data showed improved survival and meaningful inflammatory control in critically ill ventilated patients with ARDS, with observed survival rates exceeding 70%.

Operational Efficiency

Reduced operating burn and retained top scientific leaders, allowing for more efficient and less capital-intensive operations.

MiNK Therapeutics (INKT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INKT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 14, 2025	2025 (Q2)	-0.55 / -	-0.7	―	―	―
May 15, 2025	2025 (Q1)	-0.61 / -0.70	-1.1	36.36% (+0.40)	―
Mar 18, 2025	2024 (Q4)	-0.49 / -0.62	-1.6	61.25% (+0.98)	―
Nov 14, 2024	2024 (Q3)	-0.80 / -0.50	-1.5	66.67% (+1.00)	―
Aug 13, 2024	2024 (Q2)	-0.98 / -0.70	-1.8	61.11% (+1.10)	―
May 14, 2024	2024 (Q1)	-1.52 / -1.10	-1.7	35.29% (+0.60)	―
Mar 21, 2024	2023 (Q4)	-1.52 / -1.60	-2.3	30.43% (+0.70)	―
Nov 09, 2023	2023 (Q3)	-1.82 / -1.50	-1.9	21.05% (+0.40)	―
Aug 10, 2023	2023 (Q2)	-1.98 / -1.80	-1.8	0.00% (0.00)	―	―
May 11, 2023	2023 (Q1)	-2.38 / -1.70	-2.3	26.09% (+0.60)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INKT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 15, 2025	$7.50	$7.18	-4.27%
Mar 18, 2025	$8.52	$8.24	-3.29%
Nov 14, 2024	$7.94	$7.50	-5.54%
Aug 13, 2024	$8.35	$8.49	+1.68%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does MiNK Therapeutics (INKT) report earnings?

MiNK Therapeutics (INKT) is schdueled to report earning on Aug 14, 2025, Before Open (Confirmed).

What is MiNK Therapeutics (INKT) earnings time?

MiNK Therapeutics (INKT) earnings time is at Aug 14, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is INKT EPS forecast?

INKT EPS forecast for the fiscal quarter 2025 (Q2) is -0.55.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing